Find Vaborbactam manufacturers, exporters & distributors on PharmaCompass

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Virtual Booth

ACCESS ALL DATA
Browse all information
CHEMISTRY
Discover Molecule Insights

ACTIVE PHARMA INGREDIENTS

1 API Suppliers, 1 Listed Suppliers

1 API Suppliers
1 Listed Suppliers

DEVELOPMENTS

2 Drugs in Development

2 Drugs in Development

FINISHED DOSAGE FORMULATIONS

1 FDF Dossiers, 1 FDA Orange Book

1 FDF Dossiers
1 FDA Orange Book

MARKET PLACE

2 APIs

marketPlace
2 APIs

PATENTS & EXCLUSIVITIES

7 US Patents, 2 US Exclusivities

patents
7 US Patents
2 US Exclusivities

Synopsis

ACTIVE PHARMA INGREDIENTS

API Suppliers

USDMF

CEP/COS

JDMF

EU WC

KDMF

NDC API

VMF

Listed Suppliers

API REF. PRICE (USD/KG)

$ 0

MARKET PLACE

API

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

FDF Dossiers

FDA Orange Book

Europe

Canada

Australia

South Africa

Listed Dossiers

2DRUGS IN DEVELOPMENT

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

EDQM

USP

Others

PATENTS & EXCLUSIVITIES

US Patents

US Exclusivities

Health Canada Patents

DIGITAL CONTENT

Data Compilation #PharmaFlow

Stock Recap #PipelineProspector

Weekly News Recap #Phispers

News #PharmaBuzz

GLOBAL SALES INFORMATION

US Medicaid (USD)

Annual Reports (USD Million)

Finished Drug Prices

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown

Click the button for full data set

Also known as: 1360457-46-0, Rpx7009, Rpx-7009, Vaborbactam [inn], Chembl3317857, 2-[(3r,6s)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid

Molecular Formula

C₁₂H₁₆BNO₅S

Molecular Weight

297.14 g/mol

InChI Key

IOOWNWLVCOUUEX-WPRPVWTQSA-N

FDA UNII

1C75676F8V

Vaborbactam is a -lactamase inhibitor based on a cyclic boronic acid pharmacophore. It has been used in trials investigating the treatment of bacterial infections in subjects with varying degrees of renal insufficiency. In August 2017, a combination antibacterial therapy under the market name Vabomere was approved by the FDA for the treatment of adult patients with complicated urinary tract infections (cUTI). Vabomere consists of vaborbactam and [Meropenem] for intravenous administration. Vaborbactam is added to the therapy to reduce the extent meropenem degradation by inhibiting the serine beta-lactamases expressed by the microorganism of target. The treatment aims to resolve infection-related symptoms of cUTI and achieve negative urine culture, when the infections are proven or strongly suspected to be caused by susceptible bacteria.

Vaborbactam is a beta Lactamase Inhibitor. The mechanism of action of vaborbactam is as a beta Lactamase Inhibitor.

1 2D Structure

Vaborbactam

2 Identification

2.1 Computed Descriptors

2.1.1 IUPAC Name

2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid

2.1.2 InChI

InChI=1S/C12H16BNO5S/c15-11(7-9-2-1-5-20-9)14-10-4-3-8(6-12(16)17)19-13(10)18/h1-2,5,8,10,18H,3-4,6-7H2,(H,14,15)(H,16,17)/t8-,10-/m0/s1

2.1.3 InChI Key

IOOWNWLVCOUUEX-WPRPVWTQSA-N

2.1.4 Canonical SMILES

B1(C(CCC(O1)CC(=O)O)NC(=O)CC2=CC=CS2)O

2.1.5 Isomeric SMILES

B1([C@H](CC[C@H](O1)CC(=O)O)NC(=O)CC2=CC=CS2)O

2.2 Other Identifiers

2.2.1 UNII

1C75676F8V

2.3 Synonyms

2.3.1 Depositor-Supplied Synonyms

1. 1360457-46-0

2. Rpx7009

3. Rpx-7009

4. Vaborbactam [inn]

5. Chembl3317857

6. 2-[(3r,6s)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic Acid

7. 1c75676f8v

8. 1,2-oxaborinane-6-acetic Acid, 2-hydroxy-3-((2-(2-thienyl)acetyl)amino)-, (3r,6s)-

9. 2-((3r,6s)-2-hydroxy-3-(2-(thiophen-2-yl)acetamido)-1,2-oxaborinan-6-yl)acetic Acid

10. Rpx 7009

11. Unii-1c75676f8v

12. Vaborbactam [mi]

13. Vaborbactam. Rpx7009

14. Vaborbactam (usan/inn)

15. Vaborbactam [usan:inn]

16. Vaborbactam [usan]

17. Vaborbactam [who-dd]

18. Schembl620289

19. Gtpl10871

20. Vaborbactam [orange Book]

21. Dtxsid901027690

22. Vabomere (vaborbactam + Meropenem)

23. Ex-a2589

24. Bdbm50089084

25. Mfcd28502176

26. Vabomere Component Vaborbactam

27. Akos032961376

28. Carbavance Component Vaborbactam

29. Cs-6445

30. Db12107

31. Compound 9f [pmid: 25782055]

32. Ncgc00510003-01

33. (3r,6s)-

34. 1575712-03-6

35. Bv163750

36. Hy-19930

37. Vaborbactam Component Of Carbavance

38. 2-hydroxy-3-((2-(2-thienyl)acetyl)amino)-

39. D10998

40. Q27252228

41. {(3r,6s)-2-hydroxy-3-[(thiophen-2-ylacetyl)amino]-1,2-oxaborinan-6-yl}acetic Acid; 2-((3r,6s)-2-hydroxy-3-(2-(thiophen-2-yl)acetamido)-1,2-oxaborinan-6-yl)acetic Acid; 2-[(3r,6s)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic Acid; 1,2-oxaborinane-6-acetic Acid

2.4 Create Date

2012-03-05

3 Chemical and Physical Properties

Molecular Formula	C₁₂H₁₆BNO₅S
Molecular Weight	297.14 g/mol
Hydrogen Bond Donor Count	3
Hydrogen Bond Acceptor Count	6
Rotatable Bond Count	5
Exact Mass	297.0842240 g/mol
Monoisotopic Mass	297.0842240 g/mol
Topological Polar Surface Area	124 Å²
Heavy Atom Count	20
Formal Charge	0
Complexity	370
Isotope Atom Count	0
Defined Atom Stereocenter Count	2
Undefined Atom Stereocenter Count	0
Defined Bond Stereocenter Count	0
Undefined Bond Stereocenter Count	0
Covalently Bonded Unit Count	1

4 Drug and Medication Information

4.1 Drug Indication

Indicated in combination with meropenem for the treatment of patients 18 years of age and older with complicated urinary tract infections (cUTI) including pyelonephritis caused by the following susceptible microorganisms: _Escherichia coli_, _Klebsiella pneumoniae_, and _Enterobacter cloacae_ species complex.

FDA Label

Treatment of Gram-negative bacterial infections

5 Pharmacology and Biochemistry

5.1 Pharmacology

Vaborbactam shows no antibacterial activity alone; it serves to restore the antibacterial activity of other antibacterial agents such as meropenem by attenuating their degradation by inhibiting certain serine beta-lactamases of microorganisms. Vaborbactam does not decrease the activity of meropenem against meropenem-susceptible organisms. Vaborbactam in combination with meropenem, which is a penem antibacterial drug, potentiates the bactericidal actions of meropenem against carbapenem-resistant KPC-containing _Escherichia coli_, _Klebsiella pneumoniae_, and _Enterobacter cloacae_ in a concentration-dependent manner. It restored the antimicrobial activity of meropenem in animal models of infection caused by some meropenem non-susceptible KPC-producing Enterobacteriaceae.

5.2 MeSH Pharmacological Classification

Anti-Bacterial Agents

Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)

beta-Lactamase Inhibitors

Endogenous substances and drugs that inhibit or block the activity of BETA-LACTAMASES. (See all compounds classified as beta-Lactamase Inhibitors.)

5.3 FDA Pharmacological Classification

5.3.1 Active Moiety

VABORBACTAM

5.3.2 FDA UNII

1C75676F8V

5.3.3 Pharmacological Classes

Mechanisms of Action [MoA] - beta Lactamase Inhibitors

5.4 Absorption, Distribution and Excretion

Absorption

The peak plasma concentrations (Cmax) and AUC of vaborbactam increase in a dose-proportional manner. In healthy adult subjects, the Cmax following administration of multiple 2 g dose as a 3-hour infusion was 55.6 mg/L and AUC was 588 mgh/L. In patients with the same dosing regimen, the Cmax was 71.3 mg/L and AUC was 835 mgh/L at steady state. The exposure of vaborbactam in terms of Cmax and AUC are not expected to change with repeated dosing, and there was no evidence of accumulation of vaborbactam in plasma in a repeated dosing study.

Route of Elimination

Vaborbactam predominantly undergoes renal excretion, where about 75 to 95% of the dose is excreted unchanged in the urine over a 24 to 48 hour period.

Volume of Distribution

The steady-state volume of distribution of vaborbactam in patients was 18.6 L.

Clearance

The mean renal clearance for vaborbactam was 8.9 L/h. The mean non-renal clearance for vaborbactam was 2.0 L/h indicating nearly complete elimination of vaborbactam by the renal route. The clearance of vaborbactam in healthy subjects following administration of multiple doses of 2 g as a 3-hour infusion was 10.9 L/h. The clearance of vaborbactam in patients following administration of 2 g by 3 hour infusion was 7.95 L/h.

5.5 Metabolism/Metabolites

Vaborbactam does not undergo metabolism.

5.6 Biological Half-Life

The half life of vaborbactam in healthy subjects following multiple 2 g dose administration as a 3-hour infusion was 1.68 hours. The half life of vaborbactam following administration of 2 g by 3 hour infusion was 2.25 hours.

5.7 Mechanism of Action

Vaborbactam is a cyclic boronic acid pharmacophore -lactamase inhibitor that elicits potent inhibition of _Klebsiella pneumoniae_ carbapenemase (KPC) enzymes and other Ambler class A and C enzymes such as serine -lactamases that confer resistance to commonly-used antibiotics such as Carbapenems. Vaborbactam is a potent inhibitor of class A carbapenemases, such as KPC, as well as an inhibitor of other class A (CTX-M, SHV, TEM) and class C (P99, MIR, FOX) beta-lactamases. Vaborbactam interacts with -lactamases of Ambler classes A and C via precovalent and covalent binding. It exerts no inhibitory actions on class D or class B carbapenemases. The production of contemporary -lactamase by bacterial isolates potentiate the degradation of -lactam antibiotic agents, rendering them clinically ineffective and posing challenges for patients receiving the standard antibiotic therapy. In combination with meropenem, varborbactam acts as a non-suicidal beta-lactamase inhibitor that protects meropenem from degradation mediated by serine beta-lactamases such as _Klebsiella pneumoniae_ carbapenemase (KPC).

API SUPPLIERS